Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: PEN

Penumbra, Inc.

Healthcare | Medical - Devices

No licensed closing price on file for PEN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$4.34

Penumbra, Inc. (NYSE: PEN) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 20:47 UTC.

What Penumbra, Inc. does

Penumbra, founded in 2004, develops and markets medical devices for removing blood clots and treating vascular diseases through minimally invasive procedures. The company's product portfolio addresses ischemic stroke, pulmonary embolism, acute limb ischemia, and related conditions using technologies like computer-assisted vacuum thrombectomy. Penumbra sells primarily through its own sales team in the United States, most of Europe, Canada, Australia, and Singapore, as well as through distributors in select international markets.

Summarized from Penumbra, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$4.34
Return on equity12.45%

Revenue, margins & earnings

FY2021 Revenue: $748M — margin split not shown (non-operating gains)$748MFY2021FY2022: net loss $2M on revenue $847M$847MFY2022FY2023 Revenue: $1.06B — margin split not shown (non-operating gains)$1.06BFY2023FY2024 Revenue: $1.19B — margin split not shown (non-operating gains)$1.19BFY2024FY2025 Net income: $178MFY2025 Taxes & interest: $12MFY2025 Operating expenses: $753MFY2025 Cost of revenue: $461M$1.40BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16PresidentTax withholding-1,367$439.1K
  • 2026-09-17PresidentTax withholding-1,230$391.7K
  • 2026-08-19PresidentAward3,060—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Penumbra, Inc. do?

Penumbra, founded in 2004, develops and markets medical devices for removing blood clots and treating vascular diseases through minimally invasive procedures.

When did PEN last file with the SEC?

Penumbra, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 20:47 UTC. This page is also available as JSON at /api/data?ticker=PEN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PEN and 5,000+ tickers.

Create a free account — keep PEN
For your agent
GET /api/data?ticker=PEN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt